Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FERTINEX vs CHORIONIC GONADOTROPIN
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Follitropin beta, a recombinant form of human follicle-stimulating hormone (FSH), binds to the FSH receptor on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and maturation in women and spermatogenesis in men.
Chorionic gonadotropin (h CG) binds to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on the surface of gonadal cells, stimulating steroidogenesis and gametogenesis. In females, it triggers ovulation and luteinization; in males, it stimulates Leydig cells to produce testosterone.
Ovulation induction in anovulatory women with polycystic ovary syndrome (PCOS) who have failed to respond to clomiphene citrate,Controlled ovarian hyperstimulation for assisted reproductive technologies (ART) such as in vitro fertilization (IVF),Hypogonadotropic hypogonadism in men
FDA-approved: Induction of ovulation in infertile females (as part of controlled ovarian hyperstimulation),FDA-approved: Treatment of prepubertal cryptorchidism,FDA-approved: Treatment of hypogonadotropic hypogonadism in males,Off-label: Weight loss (not recommended),Off-label: In vitro fertilization protocols
For ovulation induction: 75-150 IU subcutaneously or intramuscularly once daily for 7-12 days; for spermatogenesis: 75-150 IU subcutaneously or intramuscularly 3 times per week.
For hypogonadotropic hypogonadism: 1000-2000 IU subcutaneously or intramuscularly 2-3 times per week. For ovulation induction: 5000-10,000 IU intramuscularly as a single dose.
Terminal elimination half-life is approximately 24-36 hours in patients with normal renal function, supporting once-daily dosing.
Biphasic: initial half-life ~11 hours, terminal half-life ~23–30 hours. Single-dose half-life ~32 hours; repeated dosing may extend due to accumulation.
Metabolized primarily via the liver and kidneys; exact enzymes not fully characterized, but involves hepatic degradation and renal excretion.
Primarily metabolized in the liver via proteolytic degradation; undergoes renal excretion with a half-life of 24-36 hours.
Primarily renal excretion of unchanged drug (80-90% of administered dose), with the remainder excreted as metabolites in urine and feces.
Primarily renal; intact h CG is excreted in urine. Negligible biliary/fecal elimination.
Approximately 60-70% bound to plasma proteins, primarily albumin.
Approximately 80% bound; binds to albumin and sex hormone-binding globulin (SHBG) with low affinity.
Vd is approximately 0.3-0.5 L/kg, indicating distribution mainly into extracellular fluid.
0.3–0.5 L/kg; distributes into extracellular fluid, gonadal tissues, and poorly into fat.
Subcutaneous: ~70% relative to intravenous; intramuscular: ~90% relative to intravenous.
IM/SC: ~40% to 100% (mean ~78%) due to variable absorption; IV: 100% (not typical). Oral: negligible (<1% due to degradation).
No specific dosing guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to limited data; consider reduced dose or extended interval.
No specific dose adjustment guidelines available; use with caution in severe renal impairment (GFR <30 m L/min/1.73 m²).
No specific dosing guidelines; use with caution in severe hepatic impairment (Child-Pugh class C) due to limited data; consider reduced dose.
No specific dose adjustment guidelines available; use with caution in severe hepatic impairment (Child-Pugh class C).
For delayed puberty (males): 75-150 IU subcutaneously or intramuscularly 3 times per week; adjust based on testosterone response. For cryptorchidism: 1000-1500 IU subcutaneously or intramuscularly 2-3 times per week for 4-6 weeks; not weight-based but age-adjusted.
Cryptorchidism: 500-1000 IU subcutaneously or intramuscularly 2-3 times per week for 6 weeks. Delayed puberty: 500-1500 IU subcutaneously or intramuscularly 2-3 times per week.
Elderly patients are not typically candidates for FERTINEX; no specific dose adjustments recommended due to lack of use; monitor for comorbidities and potential hypersensitivity.
No specific dose adjustments; monitor for fluid retention and cardiovascular effects.
FERTINEX should only be used by physicians with expertise in infertility treatment. Ovarian hyperstimulation syndrome (OHSS) may occur, which can be severe and result in ovarian enlargement, pelvic pain, ascites, pleural effusion, and thromboembolic events. Multiple gestation increases the risk of adverse maternal and perinatal outcomes.
None. However, use in females requires careful monitoring to avoid ovarian hyperstimulation syndrome (OHSS), which can be severe.
Risk of ovarian hyperstimulation syndrome (OHSS), which may be severe and require hospitalization,Increased risk of multiple gestation (twins, triplets, etc.),Ovarian torsion reported,Potential for ovarian enlargement and cyst formation,Thromboembolic events, especially in patients with risk factors,Should not be used in patients with primary ovarian failure, uncontrolled thyroid/adrenal dysfunction, or sex hormone-dependent tumors
Ovarian hyperstimulation syndrome (OHSS): Risk of severe OHSS with ascites, pleural effusion, and thromboembolic events,Multiple pregnancy: Increased risk due to ovulation induction,Thromboembolic events: Increased risk, especially in patients with prior history,Ovarian enlargement: Monitor with ultrasound,Hormonal-dependent malignancies: Caution in patients with prior history
Pregnancy,Lactation,Primary ovarian failure (elevated FSH levels),Uncontrolled thyroid or adrenal dysfunction,Sex hormone-dependent tumors (e.g., breast, ovarian, uterine),Hypersensitivity to follitropin beta or any component of the formulation
Pregnancy,Primary ovarian failure,Uncontrolled thyroid or adrenal dysfunction,Active thromboembolic disorder,Hormone-sensitive tumors (e.g., prostate, breast, ovarian),Hypersensitivity to h CG or any component
No specific food interactions. Maintain a balanced diet rich in folic acid (400-800 mcg/day) to reduce risk of neural tube defects. Avoid excessive alcohol and caffeine.
No known food interactions.
Fertinex (urofollitropin) is associated with a Category X risk in pregnancy. Administration during pregnancy may cause fetal harm, including congenital malformations (neural tube defects, limb defects) and spontaneous abortion. Use is contraindicated in pregnant women.
Chorionic gonadotropin is a pregnancy hormone; exogenous use during first trimester may theoretically alter placental hormone balance, but no increased risk of congenital anomalies has been established. However, use during pregnancy is contraindicated except as part of assisted reproductive technology protocols where its role is physiological. No fetal risks documented from therapeutic use in second or third trimester.
Safety during breastfeeding has not been established. Excretion in human milk is unknown; no M/P ratio available. Due to potential for serious adverse reactions in nursing infants, breastfeeding is not recommended during treatment.
Chorionic gonadotropin is not orally bioavailable and is likely degraded in infant gastrointestinal tract. Excretion into breast milk is unknown; M/P ratio not established. However, due to its protein nature, transfer is expected to be minimal. Use during breastfeeding is not recommended unless clearly necessary; theoretical risk of hormonal effects on infant.
No dose adjustments are indicated as Fertinex is contraindicated in pregnancy. Use should be discontinued if pregnancy is confirmed.
No pharmacokinetic dose adjustments are recommended in pregnancy as the drug is typically administered only prior to conception or in early pregnancy for luteal phase support. The endogenous hormone levels in pregnancy far exceed exogenous doses. No dose modification required in later trimesters because use is contraindicated.
FERTINEX (urofollitropin) is a purified FSH product used for ovulation induction. Monitor ovarian response via serum estradiol levels and transvaginal ultrasound to assess follicle size and number. Adjust dose based on response to minimize OHSS risk. Administer IM or SC after reconstitution. Use caution in patients at risk for thromboembolism.
Chorionic gonadotropin (h CG) is used to trigger ovulation in assisted reproduction and to treat hypogonadotropic hypogonadism in males. Monitor for ovarian hyperstimulation syndrome (OHSS) in women; discontinue if severe. Do not use in women with primary ovarian failure. In males, may cause gynecomastia or fluid retention.
FERTINEX is a hormone injection given under the skin or into a muscle to help you ovulate.,You will need training on how to inject the medication and dispose of needles safely.,Common side effects include headache, bloating, and injection site reactions.,Seek immediate medical attention if you experience severe pelvic pain, sudden weight gain, or shortness of breath.,Avoid alcohol and limit caffeine intake during treatment.,Report any signs of ovarian hyperstimulation syndrome (OHSS) such as nausea, vomiting, or decreased urination.
Report abdominal pain, bloating, nausea, vomiting, or rapid weight gain (signs of OHSS).,In males, report breast tenderness or swelling, or fluid retention (swollen ankles/feet).,Do not use if pregnant or breastfeeding unless directed by a specialist.,For fertility: timing of intercourse or IUI is critical; follow cycle monitoring closely.,In males: take as prescribed for testicular descent or hypogonadism; may require multiple doses.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FERTINEX vs CHORIONIC GONADOTROPIN, answered by our medical review team.
FERTINEX is a Gonadotropin that works by Follitropin beta, a recombinant form of human follicle-stimulating hormone (FSH), binds to the FSH receptor on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and maturation in women and spermatogenesis in men.. CHORIONIC GONADOTROPIN is a Gonadotropin Hormone that works by Chorionic gonadotropin (h CG) binds to the luteinizing hormone/choriogonadotropin receptor (LHCGR) on the surface of gonadal cells, stimulating steroidogenesis and gametogenesis. In females, it triggers ovulation and luteinization; in males, it stimulates Leydig cells to produce testosterone.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FERTINEX and CHORIONIC GONADOTROPIN depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FERTINEX is: For ovulation induction: 75-150 IU subcutaneously or intramuscularly once daily for 7-12 days; for spermatogenesis: 75-150 IU subcutaneously or intramuscularly 3 times per week.. The standard adult dose of CHORIONIC GONADOTROPIN is: For hypogonadotropic hypogonadism: 1000-2000 IU subcutaneously or intramuscularly 2-3 times per week. For ovulation induction: 5000-10,000 IU intramuscularly as a single dose.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FERTINEX and CHORIONIC GONADOTROPIN in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FERTINEX is classified as Category C. Fertinex (urofollitropin) is associated with a Category X risk in pregnancy. Administration during pregnancy may cause fetal harm, including congenital malformations (neural tube d. CHORIONIC GONADOTROPIN is classified as Category C. Chorionic gonadotropin is a pregnancy hormone; exogenous use during first trimester may theoretically alter placental hormone balance, but no increased risk of congenital anomalies. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.